Robbins Umeda LLP Announces An Investigation Of The Acquisition Of Valeant Pharmaceuticals International By Biovail Corporation
Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of Valeant Pharmaceuticals International ("Valeant" or the "Company") (NYSE:VRX) in connection with their actions in causing Valeant to enter into a definitive merger agreement to be acquired by Biovail Corporation ("Biovail") (NYSE:BVF). If the transaction is completed, Valeant shareholders will receive a combination of cash and stock equal to $16.77 in cash and 1.7809 shares of Biovail common stock for each share of Valeant they hold, for an implied value of approximately $46.14 per Valeant share. If approved, the transaction is expected to be completed by the end of the year.
Robbins Umeda LLP's investigation concerns whether the Board of Directors of Valeant undertook a fair process to obtain fair consideration for all shareholders of Valeant. Before the announcement of the proposed acquisition, at least two analysts had price targets of $57 per share. Nevertheless, the Company's fiduciaries are attempting to sell Valeant now at a price well below these targets.
If you are a shareholder of Valeant, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at firstname.lastname@example.org.
Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.Advertisement
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV